Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,376 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Clear all
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184
View directory record Official record
Conditions
CMV Infection
Interventions
Artesunate, Ganciclovir (GCV)
Drug
Lead sponsor
Amivas Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety

NCT02816684
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Pegasys-VR, Social Effectiveness Therapy for Children
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
7 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 20, 2026, 1:16 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia

NCT07615075
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Healthy
Interventions
Placebo, IL-23
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Caminamos: A Smartphone App to Connect With Walking Partners

NCT03059901
View directory record Official record
Conditions
Physical Activity
Interventions
Caminamos App
Other
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Palo Alto, California • Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

NCT03477175
View directory record Official record
Conditions
Solid Tumors
Interventions
E7080, Comparator Drug, Comparator Drug: Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 20, 2026, 1:16 AM EDT
Withdrawn Early Phase 1 Interventional

D-cycloserine Augmented Treatment for Youth With Tic Disorders

NCT04357951
View directory record Official record
Conditions
Tourette Syndrome
Interventions
d-cycloserine, Placebo pill, Behavior Therapy
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-Invasive Blood Test Cross-Validation Study

NCT03991637
View directory record Official record
Conditions
Reproducibility of Results, Safety Issues
Interventions
Non-Invasive Comprehensive Metabolic Panel
Device
Lead sponsor
Joseph Allen Jr.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 20, 2026, 1:16 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Investigation of Macular Pigment Augmentation on Dark Adaptation

NCT00478439
View directory record Official record
Conditions
Aging, Age-Related Macular Degeneration
Interventions
ZeaVision EyePromise Restore, Multivitamin
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Oct 20, 2026, 1:16 AM EDT
Completed No phase listed Observational

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06064656
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 20, 2026, 1:16 AM EDT
Terminated Phase 4 Interventional Results available

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse

NCT01886794
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 1:16 AM EDT
Not listed Not applicable Interventional

Negative Work Exercise for the Treatment of Knee Arthritis

NCT02098096
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
Negative Work, Stretching
Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 70 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 1:16 AM EDT
Active, not recruiting No phase listed Observational

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
BHV-4157
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

NCT05643573
View directory record Official record
Conditions
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions
Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14,830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
163
States / cities
Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 20, 2026, 1:16 AM EDT
Recruiting Phase 4 Interventional

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

NCT07316166
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
Dexmedetomidine, Ropivacaine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301
View directory record Official record
Conditions
Advanced Melanoma
Interventions
EIK1001, Pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
14
States / cities
Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Digital Wellbeing Project

NCT05061966
View directory record Official record
Conditions
Mental Health
Interventions
immi, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 19 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 20, 2026, 1:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiota-dependent Health Impacts of Haskap Berries

NCT06546020
View directory record Official record
Conditions
Metabolic Disease, Inflammation, Microbial Colonization
Interventions
Haskap berry smoothie, Placebo comparator
Dietary Supplement
Lead sponsor
Montana State University
Other
Eligibility
35 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

NCT02925650
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 20, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

NCT05199090
View directory record Official record
Conditions
Obesity
Interventions
MBL949, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

NCT02452060
View directory record Official record
Conditions
Pain, Postoperative Depression
Interventions
Ketamine, Placebo Comparator
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 20, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults

NCT03051685
View directory record Official record
Conditions
Healthy
Interventions
DFN-15 Dose 1, DFN-15 Dose 2, DFN-15 Dose 3, Active Comparator
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 20, 2026, 1:16 AM EDT